Systematic evaluation and meta-analysis on the efficacy and safety of Biqi Capsules in the treatment of knee osteoarthritis
WANG Huanrui1 WU Jiaqi2 CAI Xiao2 HUANG Runyue2,3 CHEN Xiumin2,3 HUANG Qingchun2
1.The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China;
2.Department of Rheumatology, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Province, Guangzhou 510006, China;
3.Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Province, Guangzhou 510006, China
Abstract：Objective To assess clinical effect and safety of Biqi Capsules combined with Western medicine in the treatment of knee osteoarthritis (KOA). Methods Cochrane Library, PubMed, Embase, CNKI, VIP and Wanfang databases were searched by computer, with the search time from the establishment to August 2019. Chinese key words include “Biqi Capsules, Biqi, knee osteoarthritis, knee arthritis”, etc. A randomized controlled trial on the treatment of KOA with Biqi Capsules combined with Western medicine compared with Western medicine was included. Cochrane Handbook 5.2.0 was used to analyze the quality of literature. Review Manager 5.3 was used to evaluate the overall efficiency, WOMAC score, VAS score, SF-36, adverse reactions and meta-analysis. Results Six RCTs that contained 841 patients were included. Meta analysis results: the overall effective rate of Biqi Capsules combined with Western medicine in the treatment of KOA was higher than that of Western medicine group (RR = 1.22, 95%CI [1.15, 1.29], P < 0.000 01). WOMAC score of Biqi Capsules combined with Western medicine in the treatment of KOA was lower than that of Western medicine group (MD = -10.57, 95%CI [-12.17, -8.97], P ＜ 0.000 01). Systematic evaluation results: Biqi Capsules combined with Western medicine was better than Western medicine group in reducing VAS score of KOA and improving SF-36, and there was no serious adverse event. Conclusion The result of this systematic review shows that Biqi Capsules combined with Western medicine has good clinical efficacy in KOA treatment with acceptable tolerability. However, due to the low quality and limitations of the included researches, more large-scale RCTs are needed to evaluate the long-term efficacy and safety of Biqi Capsules in the treatment of KOA.
王焕锐1 伍嘉琪2 蔡晓2 黄闰月2，3 陈秀敏2，3 黄清春2. 痹祺胶囊治疗膝骨关节炎有效性和安全性的系统评价及meta分析[J]. 中国医药导报, 2020, 17(13): 127-131.
WANG Huanrui1 WU Jiaqi2 CAI Xiao2 HUANG Runyue2,3 CHEN Xiumin2,3 HUANG Qingchun2. Systematic evaluation and meta-analysis on the efficacy and safety of Biqi Capsules in the treatment of knee osteoarthritis. 中国医药导报, 2020, 17(13): 127-131.
[1] Tang X，Wang S，Zhan S，et al. The prevalence of symptomatic knee osteoarthritis in China：results from the China health and retirement longitudinal study[J]. Arthritis Rheum，2016，68（3）：648-653.
[2] Urquhart DM，Phyomaung PP，Dubowitz J，et al. Are cognitive and behavioural factors associated with knee pain? A systematic review [J]. Semin Arthritis Rheum，2015，44（4）：445-455.
[3] Chen Y，Bedson J，Hayward RA，et al. Trends in prescribing of non-steroidal anti-inflammatory drugs in patients with cardiovascular disease：influence of national guidelines in UK primary care [J]. Fam Pract，2018，35（4）：426-432.
[4] Bally M，Dendukuri N，Rich B，et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data [J]. BMJ（Online），2017，357：j1909.
[5] Hochberg MC，Altman RD，April KT，et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand，hip，and knee [J]. Arthritis Care Res，2012，64（4）：465-474.
[6] Jevsevar DS. Treatment of osteoarthritis of the knee：evidence-based guideline [J]. J Am Acad Orthop Surg，2013， 21（9）：571-576.
[7] 中华医学会骨科学分会关节外科学组.骨关节炎诊疗指南（2018年版）[J].中华骨科杂志，2018，38（12）：705-715.
[8] 白人骁.痹祺胶囊治疗类风湿关节炎的多中心随机对照临床试验[J].中华中医药杂志，2016，31（9）：3821-3825.
[9] 王琪，王昊，王景贵，等.痹祺胶囊联合氨基葡萄糖胶囊和玻璃酸钠治疗膝骨关节炎的临床研究[J].现代药物与临床，2019，34（4）：278-283.
[10] Altman RD，Hochberg MC，Moskowitz RW，et al. Recommendations for the medical management of osteoarthritis of the hip and knee：2000 update [J]. Arthritis Rheum，2000，43（9）：1905-1915.
[11] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：353.
[12] 吴涛.痹祺胶囊联合依托考昔治疗膝骨性关节炎的临床研究[J].现代药物与临床，2018，33（5）：1145-1149.
[13] 李隶.痹祺胶囊联合尼美舒利片治疗膝骨性关节炎的临床观察[J].内蒙古中医药，2016，35（13）：84.
[14] 龚韶华，匡勇，郑煜新，等.痹祺胶囊对老年性膝关节炎的疗效及基质金属酶2/基质金属酶9表达的影响[J].世界中医药，2018，13（5）：115-118，123.
[15] 肖祥池，陈善创.痹祺胶囊治疗肝肾亏虚型膝关节炎的临床效果观察[J].广西医学，2017，39（5）：652-654.
[16] 龚幼波，张琥，杜敏，等.痹祺胶囊治疗肝肾亏虚型膝关节炎疗效及对患者红细胞免疫功能变化的影响[J].中国中医骨伤科杂志，2019，27（8）：15-19.
[17] Cross M，Smith E，Hoy D，et al. The global burden of hip and knee osteoarthritis：estimates from the Global Burden of Disease 2010 study [J]. Ann Rheum Dis，2014，73（7）：1323-1330.
[18] 刘强，洪加源，胡维界.膝骨性关节炎治疗进展[J].医学综述，2015，21（3）：474-476.
[19] 谭洪发，荣晓凤，徐艳明，等.痹祺胶囊对CIA大鼠OPG/RANKL表达的影响[J].免疫学杂志，2016，32（10）：878-883.
[20] 师咏梅，许放，柳占彪.痹褀胶囊对实验性骨关节炎大鼠MMP-3和TIMP-1的影响[J].天津中医药，2011，28（1）：64-66.
[21] 李芳，姚建华，张风肖，等.痹祺胶囊对膝骨性关节炎患者MMP-3、TIMP-1表达的影响[J].中华中医药杂志，2014，29（8）：2701-2703.
2020, Vol. 17 
京公网安备 11010502046598号